Exome sequencing identifies SLIT2 variants in primary CNS lymphoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• SLIT2 is a known tumor suppressor gene.
• Its role in primary central nervous system lymphoma (PCNSL) has not been previously established.

Purpose of the Study:

• To investigate the potential role of SLIT2 in the pathogenesis and progression of PCNSL.
• To identify novel SLIT2 variants in PCNSL patients and assess their prognostic significance.

Main Methods:

• Exome sequencing of paired tumor and blood DNA from six treatment-naïve PCNSL patients.
• Analysis of a large validation cohort of lymphoid malignancies using the cBio Cancer Genomics Portal.
• WNT- and NF-κB-reporter luciferase assays to evaluate the functional impact of identified variants.

Main Results:

• Novel SLIT2 variants (p.N63S, p.T590M, p.T732S) were identified in PCNSL patients.
• These variants were associated with shorter progression-free survival in the patient cohort.
• The variants also correlated with shorter overall survival in a broader cohort of lymphoid malignancies.
• Functional assays suggest these alterations represent loss-of-function variants.

Conclusions:

• The identified SLIT2 variants may play a role in PCNSL pathogenesis and progression.
• SLIT2 alterations have potential prognostic implications for PCNSL patients.
• Further research is warranted to elucidate the precise role of SLIT2 in PCNSL.